Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Yijun Zheng | Medicine | Best Researcher Award

Mr. Yijun Zheng | Medicine | Best Researcher Award

The Second Hospital & Clinical Medical School, Lanzhou University | China

Dr. Zheng Yijun is a dedicated medical researcher currently pursuing a PhD in Surgery at Lanzhou University. With a strong focus on the pharmacological actions of traditional Chinese medicine in cancer treatment, particularly gastric cancer, he has contributed to multiple papers, including two independent SCI publications. Dr. Zheng also serves as a reviewer for high-impact journals like Frontiers in Medicine and International Journal of Clinical Practice. He is actively involved in projects funded by the National Natural Science Foundation of China and collaborates on key provincial research initiatives.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Focus: Zheng has a clear focus on the prevention and treatment of gastric cancer through traditional Chinese medicine, a significant and relevant area of study in modern healthcare.

  • Academic Contributions: Zheng has independently authored two SCI papers, one of which has achieved a high citation rate, highlighting the impact of their work in the academic community.

  • Collaborative Research: Zheng has been involved in eight research projects, including two funded by the National Natural Science Foundation of China, which demonstrates involvement in high-impact research.

  • Peer Review Contributions: Serving as a reviewer for reputable journals such as SCI and Frontiers in Medicine showcases the recognition of Zheng’s expertise and their ability to contribute to the broader academic community.

  • Zheng Yijun demonstrates strong academic research in a promising and highly relevant field. With a focus on traditional Chinese medicine for cancer treatment, significant publications, and involvement in prestigious research projects, Zheng is well-positioned for consideration for the “Best Researcher Award.” However, expanding the breadth of their research network, increasing publication output, and gaining editorial experience would help to further solidify their candidacy for this award.

Education 🎓

Dr. Zheng is currently enrolled in the PhD program in Surgery at Lanzhou University. His academic journey is complemented by his extensive participation in research, including a review of Astragalus Polysaccharide’s pharmacological effects, published in Frontiers in Pharmacology. He has independently authored SCI papers that contribute to the field of traditional medicine’s role in cancer treatment.

Experience 💼

Dr. Zheng has participated in over eight research projects, two of which were funded by the National Natural Science Foundation of China. His work spans across the investigation of gastric cancer treatment and the pharmacological effects of traditional Chinese medicine. Additionally, Dr. Zheng has served as a reviewer for multiple high-impact journals, solidifying his expertise and credibility in the field.

Research Interest On Medicine 🔬

Dr. Zheng’s primary research interest is in the prevention and treatment of gastric cancer through traditional Chinese medicine. His research aims to provide a theoretical foundation for incorporating traditional medicine in cancer therapy, with a specific focus on polysaccharides and their pharmacological actions in tumor treatment.

Award 🏆

Dr. Zheng is a nominee for the Best Researcher Award at the Forensic Scientist Awards, due to his significant contributions to the field of medical research, particularly in the application of traditional Chinese medicine for tumor treatment. His innovative work and high citation rate highlight his impact in medical research.

Publications 📚

  1. Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Front Pharmacol. 2020 Mar 24; 11:349. Link

    • Cited by: 348 articles (SCI citation)

  2. Zheng Y, Zhang Y, Wang Z, Guo X, Zhang L, Zhang Y. “Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.” Discov Oncol. 2025 Apr 24; 16(1):606. Link

    • Cited by: 98 articles (SCI citation)

Conclusion 🌍

Dr. Zheng Yijun is an emerging leader in the field of medical research, particularly in the application of traditional Chinese medicine for cancer treatment. His dedication to advancing the understanding of gastric cancer and its treatment methods has already resulted in significant publications and recognition. As a nominee for the Best Researcher Award, his future in medical research looks promising, with continued contributions to the development of effective cancer therapies.